People · Operator
Named in public records as an officer, director or promoter · active 2017–2026 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kitov Pharma Ltd. | — | Pharmaceuticals | Series A | $42.6M | $23.2M | 2017 |
| Nasus Pharma Ltd | — | Biotechnology | Series B | $15.0M | $53.6M | 2026 |
Isaac Israel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Isaac Israel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Sharon Shacham | 1 | 4 |
| Eric Rowinsky | 1 | 4 |
| Dalia Megiddo | 1 | 3 |
| Avraham Ben-Tzvi | 1 | 3 |
| Ronnie Hershman | 1 | 2 |
| Robert Gagnon | 1 | 2 |
| Bertrand Liang | 1 | 2 |
| Steven Steinberg | 1 | 2 |
| Udi Gilboa | 1 | 2 |
| Dan Teleman | 1 | 2 |
| Yael Margolin | 1 | 2 |
| David Silberman | 1 | 2 |
| Ori Hershkovitz | 1 | 2 |
| Gil Ben-Menachem | 1 | 1 |
| John Paul Waymack | 1 | 1 |
| Arye Weber | 1 | 1 |
| Eyal Rubin | 1 | 1 |
| Lior Fhima | 1 | 1 |
| Ido Morpurgo | 1 | 1 |
| Michael Schickler | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.